Kornimate/medical-research-clean huggingface dataset:
solar lighting to reduce indoor air pollution in rural uganda

Conditions: Pollution; Exposure; Hypertension; Pollution Related Respiratory Disorder

Summary: this study evaluates the impact of a solar lighting system on kerosene lamp use, levels of indoor air pollution, and health in women living in rural uganda. half of the participants will receive the lighting systems immediately, while the other half will receive them after an 18 month delay.

one fifth of the global population relies on kerosene lamps for lighting, yet few studies have focused on kerosene lighting as a source of indoor air pollution. in our preliminary studies performed in uganda, we show that homes using solar lighting have much lower levels of indoor air pollution compared to homes using kerosene lighting. the primary goal of this study is to determine the extent to which solar lighting will reduce kerosene use and indoor air pollution in rural uganda, whether this intervention improves lung health, and to identify the role bacteria in our gut have on determining whether or not people will get sick from indoor air pollution.

Eligibility criteria:
inclusion criteria: * women living in nyakabare parish, uganda with no prior history of chronic lung disease exclusion criteria: * current active tuberculosis in any family member

Keywords: household air pollution fine particulate matter kerosene
expressive writing for covid-19 resilience

Conditions: Distress Due to COVID-19

Summary: the purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the covid-19 pandemic during spring 2020.

the purpose of this study is to determine the impact of a 6-week, virtually-delivered expressive writing intervention on resilience in a cohort of individuals currently navigating the covid-19 pandemic during spring 2020. eligible subjects will be adults who are able to read and write in english and are cognitively able to provide informed consent. potential subjects will be recruited through the duke health \& well-being email lists. the entirely virtual 6-week expressive writing intervention will be delivered via zoom, redcap, and email, and subjects will complete measures at baseline, 6 weeks, and 10 weeks (1 month post-intervention). each week of the intervention will invite participants to complete a series of expressive writing assignments designed to support emotional expression and cultivate resilience, and the assignments will take approximately 60-90 minutes each week to complete. the primary outcome is the 25-item connor-davidson resilience scale (cd-risc). other measures will include a basic demographics survey, questions about covid-19 impact, post-writing surveys collected after the writing assignments, the 10-item perceived stress scale (pss), the center for epidemiologic studies depression scale-revised, and the 21-item post -traumatic growth inventory (ptgi). participants will also have the option to share the content of their writing assignments with the research team if they choose. the risks of participation in this study are minimal and include the risk of mild sadness after the writing assignments and the risk of loss of confidentiality.

Eligibility criteria:
inclusion criteria: potential subjects will be considered eligible if they feel they have been personally impacted by circumstances surrounding covid-19. other eligibility criteria include: * able to speak, read, write, and understand english * cognitively able to provide consent * ability to participate in a 6-week intervention delivered via zoom, redcap, and email
quality of life before and after transcatheter ablation in children with arrythmias

Conditions: Arrhythmia

Summary: the goal of this clinical trial is to evaluate the improvement in the quality of life after the transcatheter ablation in children from 5 to 17 years old suffering for arrythmia who need a transcatheter ablation (according to paces recommendations). the main question is: • to evaluate an improvement in the quality of life in these children, according to different questionnaires? participants will answer some questionnaires to get a global evaluation of the quality of life: * peds ql 4.0 * peds ql 4.0 by proxy, which will be completed by the parents * ricci and gagnon questionnaire * child depression index * state and trait anxiety inventory


Eligibility criteria:
inclusion criteria: * patients aged 8 to 17 * patients with a rhythm disorder, * patients with indication for catheter ablation according to paces (pediatric and congenital electrophysiology society) recommendations, * patients and/or their parents/legal guardians who have given their non-objection to the study. exclusion criteria: * refusal of child or parents/legal guardians * unability to understand and/or fill the quality of life questionnaire

Keywords: children arrythmia transcatheter ablation quality of life
dexamethasone to target stress and immune system mechanisms underlying alcohol craving

Conditions: Alcohol Use Disorder

Summary: this is a double-blind, placebo-controlled, proof of concept laboratory study to recruit n=70 (35 males / 35 females) non-treatment seeking, heavy drinkers with alcohol use disorder (aud). it is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving during stress by decreasing basal cortisol, increasing anti-inflammatory cytokine levels and potentially normalizing the immune response to stress.


Eligibility criteria:
inclusion criteria: * non-treatment seeking heavy drinking men and women with aud * age range 18-55, * body mass index (bmi) of 18-35 * positive ethylglucuronide (etg) urine toxicology screen for alcohol * able to provide informed written and verbal consent * able to read english and complete study evaluations * good health as verified by screening examination. exclusion criteria: * meet criteria for substance use disorder (sud) or other psychoactive substances, excluding nicotine * unable to remain abstinent for five days * need for a medically assisted detoxification * regular use of steroids, anticonvulsants, sedatives/hypnotics, prescription analgesics, other anti-hypertensives, anti-arrythmics, antiretroviral medications, tricyclic antidepressants, naltrexone, disulfiram, and any other psychoactive medications with the exception of stabilization on selective serotonin re-uptake inhibitors (ssris) * psychotic or severely psychiatrically disabled * significant underlying medical conditions which would be of potential harm * pregnancy or breast feeding women; * women using monophasic contraceptives * electrocardiogram (ekg) evidence of clinically significant conduction abnormalities, (bazlett's corrected qt (qtc) interval of \>450 msec for men and qtc\>470 msec for women).

Keywords: stress dexamethasone immune system cortisol
extracardiac complications after cardiac surgery

Conditions: Acute Lung Injury; Sepsis; Infections; Acute Kidney Injury

Summary: hypothesis of the study is that patients undergoing major cardiac surgery can develop extracardiac complications correlated to cardiopulmonary by pass.

to find out which are the main peri operative predictors of acute lung injury and other extracardiac complications, such as kidney injury, that prolonged intensive care unit (icu) length of stay after cardiac surgery. the main goal is to evaluate whether mechanical ventilation, in particular tidal volume, can be predictor of acute lung injure in this kind of patients.

Eligibility criteria:
inclusion criteria: * cardiac intervention with cardiopulmonary by pass, age \> 18 years old exclusion criteria: * off-pump surgery, heart and lung transplantations, patients on mechanical ventilation before intervention or admitted to intensive care unit (icu) before intervention.
liposomal bupivacaine for postoperative pain control in urologic procedures

Conditions: Urinary Tract Diseases

Summary: a prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.

a prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries. subjects of prospective study will be randomly divided using electronic program into two groups: the first group will receive intraoperative local liposomal bupivacaine injection at the port placement site. the control group will receive will local marcaine (bupivacaine hcl) injection primary outcome measures: * total opioid consumption measured in intravenous morphine equivalents dose during the postoperative hospital stay * postoperative pain assessment using visual analog pain scores \& brief pain inventory form. * length of hospital stay * time to first opioid use. * postoperative constipation , paralytic ileus

Eligibility criteria:
inclusion criteria: * patients undergoing urologic surgery. exclusion criteria: * pregnant and/or nursing mothers. * allergy to bupivacaine. * history of drug/alcohol abuse. * severe cardiovascular, hepatic, renal disease or neurological impairment.

Keywords: bupivacaine minimally invasive surgical procedures
mirtazapine in alzheimer-associated weight loss

Conditions: Alzheimer's Disease; Weight Loss; Mixed Dementia; Dementia

Summary: weight loss is a frequent problem associated with alzheimers disease (ad). mirtazapine has weight loss as a frequent side effect. the aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with ad or mixed dementia (ad + vascular).


Eligibility criteria:
inclusion criteria: * ad or mixed dementia * documented weight loss * mirtazapine 30 mg explicitly prescribed against weight loss exclusion criteria: * no treatment compliance * other causes of weight loss * other interventions against weight loss
parents of pediatric solid organ transplant recipients: transition to home and chronic illness care

Conditions: Transplant

Summary: the overall long term objective of this research is to improve health care utilization and quality of life of pediatric solid organ transplant recipients and family. understanding the process of transition to a chronic medical condition during the acute (3 weeks after transplant) and long term (3 and 6 months) will significantly guide the development of clinical interventions aimed at maximizing adherence and family psychosocial adjustment.

parents of children that have received a heart, kidney, liver or lung transplant will be invited to participate in this protocol. involvement in this study entails completion of questionnaires at 4 separate time points. parents will first complete questionnaires regarding discharge teaching, care coordination and readiness for hospital discharge on the day of discharge from the hospital. parents will subsequently complete questionnaires at 3 weeks, 3 months and 6 months after discharge. the post discharge questionnaires assess coping, family management, adherence and utilization of healthcare resources. currently, no research has been conducted related to readiness for hospital discharge of a parent as the primary caregiver for a child with solid organ transplant or the sequential relationships between hospitalization care and the trajectory of post-discharge outcomes. this research will fill the gap in knowledge needed for care of solid organ transplant children and parents. the ability to identify factors in the first year after transplant that are predictive of decreased coping and non-adherence affords an opportunity to develop nursing and health interventions that have significant implications for care decisions, as well as disease activity and health care costs.

Eligibility criteria:
inclusion criteria: 1. the parent's child has undergone a heart, kidney, liver, lung or multivisceral transplant and is being discharged home from the hospital 2. the parent is english speaking (tools being used have been validated for english participants only) 3. the parent is 18 years of age or older exclusion criteria: 1. presence of significant communication or cognitive impairment on the part of the parent that would preclude completion of questionnaires based on self-report 2. the child has already experienced the discharge to home transition after a previous transplant.

Keywords: transplant, pediatric
evaluation of the efficacy of electromagnetic therapy on postoperative surgical pain after uni- and bilateral inguinal hernia repair.

Conditions: Inguinal Hernias

Summary: a monocentric interventional randomized placebo controlled trial evaluating the efficacy of the post surgical and wound care recovery kit. it's a small device that consists of a thin metal ring that is placed on the skin surface, non-invasively. it's connected with a small battery. when the plastic tag is removed and the button is pushed the device is activated. within the ring a pulsed electromagnetic field is created. it influences the receptor-ligand binding at the cell surface and might improve wound healing by diminishing wound edema and inflammation. it possibly helps reducing the inflammatory reaction induced by surgery. patients will be treated for uni or bilateral inguinal hernias and at the end of surgery, at the time of bandage, a kit will be applied at the level of the incision. one group will at random receive a working device, the other half will have a kit without active electromagnetic field. postoperative analgesic consumption will be measured in a diary and pain and quality of life will be measured using visual analogue scale and eurahs-quality of life questionnaires. the aim of this study is to evaluate whether the placement of the device reduces the acute postoperative pain and whether it reduces the incidence of chronic groin pain.


Eligibility criteria:
inclusion criteria: * written informed consent from the patient * primary, unilateral and bilateral groin hernias exclusion criteria: * no written informed consent * recurrent hernias * 'incarcerated' hernias * pregnant women: reaction of a pulsed electromagnetic field on the foetus is unknown * patients with pacemaker or internal defibrillator

Keywords: inguinal hernia
perceptual learning improve visual function in patients with keratoconus

Conditions: Keratoconus, Stable

Summary: this project aims at non-progressive keratoconus patients with unsatisfactory visual acuity corrected by spectacles, and explores the effectiveness and maintenance of visual acuity improved by perceptual learning.


Eligibility criteria:
inclusion criteria: 1. aged 9 years or older; 2. has been diagnosed as keratoconus,bad-d≥2.6; 3. change of kmax \< 1.0 d and change of bad-d \<0.4175 betweem the last two pentacam result; 4. the best corrected visual acuity of both eyes was between 0.1 and 1.0; 5. has voluntarily agreed to participate in the study by signing the statement of informed consent. exclusion criteria: 1. has history of acute keratoconus; 2. has other eye diseases or other diseases/conditions causing vision loss; 3. has eye surgery history in the past 1year; 4. is currently using local/systemic medications or other interventions that may affect visual function; 5. receiving other treatments that may affect the results of this study, such as contact lenses during the study; 6. has any known neurological diseases; 7. participating in other studies currently that may affect the results of this study; 8. study other reasons that the physician considers inappropriate for inclusion in the program.
comparative effectiveness analysis of granulocyte colony stimulating factor originator products versus biosimilars

Conditions: Cancer, Breast; Cancer, Lung; Cancer of Colon; Cancer of Pancreas; Cancer, Ovarian; Lymphoma, Non-Hodgkin

Summary: this comparative effectiveness and descriptive retrospective cohort study will evaluate safety and effectiveness outcomes among commercially insured adults who received a granulocyte colony stimulating factor (g-csf) biosimilar or originator product during the first cycle of clinical guideline-indicated intermediate or high febrile neutropenia risk chemotherapy.

this comparative effectiveness and descriptive retrospective cohort study includes commercially insured adults enrolled in one of four health plans participating in the biologics and biosimilars collective intelligence consortium (bbcic) distributed research network. the investigators included patients who received a granulocyte colony stimulating factor (g-csf) biosimilar or originator product during the first cycle of clinical guideline-indicated intermediate or high febrile neutropenia risk chemotherapy. the investigators will collect patient demographics, cancer diagnosis, chemotherapy regimen, and patterns of g-csf biosimilar and originator product use. the investigators will follow patients from first g-csf exposure until up to six cycles of chemotherapy receipt, death, or insurance disenrollment. the primary effectiveness outcome is incidence of febrile neutropenia. secondary outcomes include incidence of adverse events and trends in product use over time. the investigators will compare febrile neutropenia incidence between originator and biosimilar products using inverse probability weighting to control for confounding. secondary analyses will examine 'as treated' outcomes.

Eligibility criteria:
inclusion criteria: * patients age 20 or older * diagnosis of lung, breast, colon, ovarian, pancreatic, testicular, cervical, uterine, or nhl cancer * beginning intermediate or high neutropenia risk chemotherapy exclusion criteria: * one inpatient or two outpatient cancer diagnoses at least 30 days apart in the 183 days prior to the index date for cancer different from enrolling cancer diagnosis * any of the following in 183 days prior to index date: * any chemotherapy or g-csf product receipt * 2\< medical claims at least 30 days apart for a skilled nursing facility or hospice care * 2\< diagnoses/procedure codes at least 1 day apart for cancer-related radiotherapy, bone marrow or stem cell transplant, diagnosis of hiv/aids, severe hepatic disease, chronic kidney disease, or any non-oncology related neutropenia

Keywords: colony stimulating factor
a trial of axs-05 in patients with major depressive disorder

Conditions: Depression; Major Depressive Disorder

Summary: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial of axs-05 in patients with major depressive disorder (mdd).

this study will evaluate axs-05 in a randomized, double-blind, placebo-controlled study in patients with mdd. eligible patients will be randomized in a 1:1 ratio to treatment with axs-05 or placebo for 6 weeks.

Eligibility criteria:
key inclusion criteria: * age 18 - 65 * currently meets dsm-5 criteria for mdd * body mass index between 18 and 40 kg/m\^2, inclusive key exclusion criteria: * suicide risk * history of treatment resistance in current depressive episode * history of electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation or any experimental central nervous system treatment during the current episode or in the past 6 months * pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study

Keywords: depressive disorder depressive disorder, major bupropion dextromethorphan mdd dopamine reuptake inhibitor axs-05 nmda receptor antagonist central nervous system cns sigma-1 receptor agonist nicotinic acetylcholine receptor antagonist norepinephrine reuptake inhibitor glutamate modulator axsome therapeutics gemini serotonin reuptake inhibitor
a randomized trial of 24-week versus 48-week courses of peginterferon plus ribavirin for patients with genotype 1 hepatitis c and il28b cc polymorphism

Conditions: Chronic Hepatitis C

Summary: patients with hcv genotype 1 and il28b cc polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks hcv treatment. our hypothesis is that there is no important difference in effect between the two treatment effect.


Eligibility criteria:
inclusion criteria: * age \> 18 years * serum hepatitis c rna \> 10,000iu/ml * hepatitis c virus genotype 1 * il28b cc polymorphism exclusion criteria: * previous treatment for chronic hepatitis c * clinical or biological evidence of acute hepatitis, including serum alt or ast \> 300u/ml * hiv antibody positive, hepatitis b surface antigen positive or known diagnosis of other chronic liver disease * contraindications to pr-based treatment: * uncontrolled psychiatric illness * active substance dependency * known autoimmune disorder * untreated thyroid disease * uncontrolled seizure disorder * pregnancy, lactation or inability to maintain contraception * chronic kidney disease w/ estimated gfr\< 60 * anc\<1.5/nl, hb\<12g/dl, or platelets\<75/nl * clinical or biochemical evidence of decompensated liver disease including: * history of encephalopathy * ascites * variceal bleeding * bilirubin \> 3g/dl or inr \> 1.5 * life threatening disorder with expected median survival less than 5 years * inability to comply with drug regimens or testing schedule required for study
evaluation of bd glucan in peritoneal fluid for the diagnosis of fungal peritonitis

Conditions: Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis

Summary: invasive candidiasis has a high mortality rate, around 40%. outcome remains tightly linked to the time of treatment administration. routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). it is important to develop diagnostic tools to initiate antifungal therapy as early as possible. the b d glucan detection, one of the major components of the candida cell wall, can be useful for a early diagnosis. there are several techniques on the market for the detection of glucan. in europe and america, the most used is fungitell (associated of cape cod, inc). there is several studies about the use of such kits for fungemia. a number of studies are reporting evidences of a early diagnosis. but, in medical literature, there isn't study focused on the detection of b d glucan in peritoneal fluid for candida peritonitis diagnosis.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * written informed consent for inclusion in the study * stay in intensive care unit * diagnosed with a peritonitis * peritoneal fluid collected by a surgery or radiology procedure, analysed at bacteriology laboratory of l'institut des agents infectieux, l'hôpital de la croix rousse exclusion criteria: * pregnant woman * moribund patient
oral antidiabetics effect on visceral fat

Conditions: Abdominal Obesity; Type 2 Diabetes

Summary: weight control is an essential part of treatment for type 2 diabetes (t2d) patients. weight loss is associated with decreased haemoglobin a1c (a1c) levels. in particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. quantification of visceral fat with bioimpedance (bia) is closely related to measurement with computed axial tomography. different available oral antidiabetics cause weight loss and total body fat (biguanides, dpp-4 inhibitors and sglt-2 inhibitors), but it has only been shown that slgt2 inhibitors decrease visceral fat. therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with bia in t2d patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, dpp4 inhibitors and sglt2 inhibitors.


Eligibility criteria:
inclusion criteria: * adult patients +18 years * patients with visceral fat quantification by bia at baseline and week twelve * patients with body mass index \>25 * patients can swallow tablets exclusion criteria: * patients treated with other oral antidiabetic agents or insulin * glomerular filtration rate less than 30 ml/min * transaminemia greater than 2 times the upper reference value * pregnancy * malnutrition